Investigational drug · Phase 2
SIR2501
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Chemotherapy-induced Peripheral Neuropathy.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "SIR2501"
First trial start
2026
Aug 21, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SIR2501", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chemotherapy-induced Peripheral Neuropathy
Approved drugs for the same conditions: Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "SIR2501" as an intervention, largest first.
Sironax USA, Inc.Industry
NCT07765446 · 18 participants (planned) · Start Aug 21, 2026 · Primary completion Dec 31, 2027
Drug: SIR2501 · For: Chemotherapy-induced Peripheral Neuropathy
Sites: Hollywood, Florida; Baltimore, Maryland; Boston, Massachusetts · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- NAD and NADPH in Neuronal Injury and Degeneration.
Savin SS, Atroshenko DL, Chubar TA, et al. · Biochemistry (Mosc) 2026
Also in development for Chemotherapy-induced Peripheral Neuropathy
- VMD-3866Phase 21 trial
VM Therapeutics LLC · Chemotherapy-induced Peripheral Neuropathy, Chemotherapy-induced Neuropathic Pain, CIPN - Chemotherapy-Induced Peripheral Neuropathy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.